Introduction of IMF JAPAN
Hiroyuki HATA, MD, PhD.
Department of Hematology, Kumamoto University Hospital
Consultant physician for IMF JAPAN
IMF JAPAN
International Myeloma Foundation Japan
Founded by Akira Horinouchi on October 1997.
Myeloma patients in JAPAN
Member of IMF JAPAN
age
IMF JAPAN
Consultant physicians
62 experienced doctors in all over the
country
Activities
Translation of foreign manuscripts
Response to second opinion
Attending patient seminars
IMF JAPAN
Patient seminar (Nov. 2005, Kyoto)
IMF JAPAN
Translation
FDA0LMDS0k[þ 0Y0<0ì0Ö0ê0ß0É0nb·S·
0k}s0M
0 s¨sÄ·k`£0k[þ 0W
0f0,·Å·0j[égû 0'^L0F0S0h0'
IMF0og_... 0Y0<
IMF LOOKS FORWARD TO RAPID REVIEW OF REVLIMID FOR MYELOMA PATIENTS
FOLLOWING FDA APPROVAL FOR MDS
^@m²u¾`£
0x0ne°...¬0nb·S·
0o0 s¨sÄ·k
0g0n·è^SSfs0k0^0D}Pgoe0'SÊ0| 0Y0g0W
00F
New Drug Approved for Blood Disorder Also Demonstrates Positive Results in Myeloma Clinical Trials
ÿ2005^t 12g 28eåÿ
Y·è0kQú0YX4T ÿN;l»S; 0kcÐy:0Y0<0j0iÿ0o_Å0ZS3e0hSYe
ÿ,ñSz
ÿ0nN!e¹ 0'Qú0W
0f0O
0`0U0D0
0«0ê0Õ0©0ë0Ë0¢]Þ0Î0ü0¹0Ï 0ê0¦ 0Ã0É0k0B0s¨sÄ·kOE¡Vã
ÿ0ox
North Hollywood, CA, December 28, 2005 -- The International
zv0'0µ0Ý0ü0È
0W
0 s¨sÄ·k
0n`£ 0U
0"0 0T[¶eÏ 0 xzv 0,,S;^+ 0k0 eY²0
Myeloma Foundation - supporting research and providing education,
e/cô 0,,0µ0Ý0ü0È
0'cÐO>
0W
0f 0D0~0Y0L0 g,eås¨sÄ·k
0n`£ 0U0"0x0n
advocacy and support for myeloma patients, families, researchers and
Revlimid (0ì 0Ê0ê0É0Þ0¤0Éÿ0n0ì 0Ó0å0ü0Leé 0~0<0S0h0'g_... 0Y0<0hvz^h0W physicians - today said it anticipates rapid review of Revlimid
0~0W
0_0 0 s¨sÄ·k
0o0~0_0 Yvz`'s¨sÄ·k0h0,
T| 0p0OE0f0 kÎ^t ÿ ÿ ÿ ÿÿ ÿ
(lenalidomide) for patients with myeloma, also called multiple
Nº0LN¡0O
0j 0<0h 0H0
0OE0f0D0
0n0L0"0g0Y0
myeloma, a cancer of bone marrow cells that causes an estimated
Celgene Corporation0K0
0nRevlimid0o0 MDSÿs¨sÄup_bbuÇP·¤ÿ0h
60,000 deaths each year. Revlimid from the Celgene Corporation was
T| 0p0OE0<
`ª`'^@m²u¾`£0n`£ 0U
0"0nN·è0nl»vB0npº 0k0 FDA0k0^0S just approved by the Food and Drug Administration to treat certain
b·S·
0'S×0Q0_0p0K0S
0g0Y0 0 0W
0K0W
0 {, !b vø·è^SSfs0g0o0 Revlimid
patients with a malignant blood condition called MDS. However, the
0o0 NÖ0nl»vBlÕ0K0
0,
Q·vz0W
0_`£ 0U
0"0,
T+0"0g0 s¨sÄ·k
0n`£ 0U
0"
Foundation noted that in phase III clinical studies Revlimid has also
0ggR¹ 0j }Pgoe0LS·
0·0
0OE0f0D0<0S0h0,
R 0K0c0f0D0~0Y0
demonstrated efficacy in myeloma patients, including those who have
relapsed following other treatments.
Operated by 12 volunteers and 7 doctors, Courtesy from M. Namai
IMF JAPAN
A
k
i r a
H
o
r i n
o
u
c
h
i
A
w
a
r d
2001
Masahiro Abe
Tokushima Univ.
Research of mechanisms regulating bone absorption and its contribution for
myeloma progression
2002
Takashi Sonoki
Kumamoto Univ.
Development of new therapeutic approach targeting unique features of
myeloma cells
2003
Hideaki Ishikawa
Yamaguchi Univ.
Research of new molecules regulating myeloma cell growth and it's possible usage as
targets of therapeutic agents
2004
Yutaka Hattori
Keio Univ.
Development of anti-angiogenesis and gene therapy for multiple myeloma
2005
Eiji Ashihara
Kyoto Univ.
Development of a new therapeutic approach combining molecular targeted and
immune therapy for multiple myeloma.
IMF JAPAN
Petition against Japanese government
January 2006
Rapid and evolutional improvement of strategy
for management of cancers
Rapid approval of thalidomide, lenalidomide,
bortezomib and bisphosphonates
Establishment of safety instruction for
thalidomide subscription
IMF JAPAN
Sharing knowledge
Act against myeloma
Information
from
IMF in other countries
Scientific meeting
Published manuscripts
Medial Stuff
Specialized physicians
Patients
General Physicians
&
Orthopedist
Families
Co-medical stuff
IMF JAPAN
Japan Clinical Oncology Group (JCOG)
Government
Japan Myeloma Study Group (JMSG)
IMF JAPAN